A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is not being conducted in the United States. Vildagliptin is an oral antidiabetic
agent. This 12-week clinical study is to evaluate the effect of vildagliptin 50mg qd, 50mg
bid or 100mg qd compared to placebo in patients with type 2 diabetes.